METHYLPHENIDATE HYDROCHLORIDE (CD)- methylphenidate hydrochloride capsule, extended release
Teva Pharmaceuticals USA, Inc.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES (CD) safely and effectively. See full prescribing information for METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES (CD). METHYLPHENIDATE HYDROCHLORIDE extended-release capsules (CD), for oral use, CII Initial U.S. Approval: 1955 WARNING: ABUSE AND DEPENDENCESee full prescribing information for complete boxed warning.
INDICATIONS AND USAGEMethylphenidate hydrochloride extended-release capsules (CD) are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 15 years of age (1) DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSExtended-release capsules: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg (3) CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions (≥5% and twice the rate of placebo) were anorexia and insomnia (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch DRUG INTERACTIONS
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 11/2022 |
CNS stimulants, including methylphenidate hydrochloride extended-release capsules (CD), other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9.2, 9.3)].
Methylphenidate hydrochloride extended-release capsules (CD) are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 15 years of age.
Prior to initiating treatment with methylphenidate hydrochloride extended-release capsules (CD), assess for the presence of cardiac disease (i.e., perform a careful history including family history of sudden death or ventricular arrhythmia, and physical examination) [see Warnings and Precautions (5.2)].
Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy. Maintain careful prescription records, educate patients about abuse, monitor for signs of abuse and overdose, and periodically re-evaluate the need for methylphenidate hydrochloride extended-release capsule (CD) use [see Boxed Warning, Warnings and Precautions (5.1), Drug Abuse and Dependence (9)].
The recommended starting dose of methylphenidate hydrochloride extended-release capsules (CD) is 20 mg once daily. Dosage may be adjusted in weekly 10 mg to 20 mg increments to the maximum recommended dose of 60 mg per day.
Dosage should be individualized according to the needs and responses of the patient.
Pharmacological treatment of ADHD may be needed for extended periods. Periodically re-evaluate the long-term use of methylphenidate hydrochloride extended-release capsules (CD), and adjust the dosage as needed.
Administer methylphenidate hydrochloride extended-release capsules (CD) orally once daily in the morning, before breakfast.
Swallow the capsule whole with the aid of liquids. Alternatively, open the capsule and sprinkle the contents onto a small amount (tablespoon) of applesauce and administer immediately. Do not store for future use. Drink fluids following the intake of the sprinkled capsule contents with applesauce. The capsules and the capsule contents must not be crushed or chewed.
If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage or, if necessary, discontinue methylphenidate hydrochloride extended-release capsules (CD). If improvement is not observed after appropriate dosage adjustment over a one-month period, discontinue methylphenidate hydrochloride extended-release capsules (CD).
Methylphenidate hydrochloride extended-release capsules (CD) are available in the following dosage strengths (see Table 1):
Strength |
Capsule Color |
Imprinting on Capsule Cap |
10 mg |
light green opaque cap/white opaque body |
“93” over “5295” |
20 mg |
light turquoise blue opaque cap /white opaque body |
“93” over “5296” |
30 mg |
light brown opaque cap/white opaque body |
“93” over “5297” |
40 mg |
light brown opaque cap/white opaque body |
“93” over “5298” |
50 mg |
light blue opaque cap/white opaque body |
“93” over “5292” |
60 mg |
white opaque cap/white opaque body |
“93” over “5293” |
Methylphenidate hydrochloride extended-release capsules (CD) are contraindicated in patients with:
CNS stimulants, including methylphenidate hydrochloride extended-release capsules (CD), other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy [see Drug Abuse and Dependence (9.2, 9.3)].
Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulant treatment at recommended doses. Sudden death has been reported in pediatric patients with structural cardiac abnormalities and other serious heart problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during methylphenidate hydrochloride extended-release capsule (CD) treatment.
CNS stimulants cause an increase in blood pressure (mean increase approximately 2 mmHg to 4 mmHg) and heart rate (mean increase approximately 3 bpm to 6 bpm). Individuals may have larger increases. Monitor all patients for hypertension and tachycardia.
Exacerbation of Pre-Existing Psychosis
CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.
Induction of a Manic Episode in Patients with Bipolar Disorder
CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).
New Psychotic or Manic Symptoms
CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. If such symptoms occur, consider discontinuing methylphenidate hydrochloride extended-release capsules (CD). In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared to 0 in placebo-treated patients.
Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate products in both pediatric and adult patients. Priapism was not reported with drug initiation but developed after some time on the drug, often subsequent to an increase in dose. Priapism has also appeared during a period of drug withdrawal (drug holidays or during discontinuation). Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.
CNS stimulants, including methylphenidate hydrochloride extended-release capsules (CD), used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.
CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.
Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development.
Closely monitor growth (weight and height) in pediatric patients treated with CNS stimulants, including methylphenidate hydrochloride extended-release capsules (CD).
Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.
The following are discussed in more detail in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical trials experience with methylphenidate hydrochloride extended-release capsules (CD) included 188 pediatric patients 6 to 15 years old with ADHD exposed to methylphenidate hydrochloride extended-release capsules (CD). Patients received methylphenidate hydrochloride extended-release capsules (CD) 20 mg, 40 mg, and/or 60 mg per day. The 188 patients were evaluated in the following studies: Study 1, a 3-week placebo-controlled clinical study consisting of a total of 314 pediatric patients (ages 6 to 15 years; methylphenidate hydrochloride extended-release capsules (CD) n=155); Study 2, a placebo-controlled, crossover clinical study consisting of 25 pediatric patients (ages 7 to 12 years); and Study 3, an uncontrolled clinical study consisting of 8 pediatric patients (ages 6 to 10 years).
Adverse Reactions Leading to Discontinuation of Treatment
In the 3-week placebo-controlled, parallel-group trial, two methylphenidate hydrochloride extended-release capsules (CD)-treated patients (1%) and no placebo-treated patients discontinued due to an adverse reaction (rash and pruritus; and headache, abdominal pain, and dizziness, respectively).
Most Common Adverse Reactions
The most common adverse reactions that occurred in 5% or more of patients treated with methylphenidate hydrochloride extended-release capsules (CD) in a pool of Studies 1, 2 and 3 (ages 6 to 15 years) where the incidence in patients treated with methylphenidate hydrochloride extended-release capsules (CD) was at least twice the incidence in placebo-treated patients were anorexia and insomnia.
Adverse reactions that occurred in ≥5% of patients treated with methylphenidate hydrochloride extended-release capsules (CD) and greater than placebo in pooled Studies 1, 2, and 3 are presented in Table 2:
Body System |
Preferred Term |
Methylphenidate Hydrochloride Extended-Release Capsules (CD) |
Placebo |
% |
% |
||
General |
Headache |
12 |
8 |
Abdominal Pain (stomachache) |
7 |
4 |
|
Digestive System |
Anorexia |
9 |
2 |
Nervous System |
Insomnia |
5 |
2 |
The following adverse reactions have been identified during postmarketing use of methylphenidate hydrochloride extended-release capsules (CD) and other methylphenidate hydrochloride products. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse Reactions with methylphenidate hydrochloride extended-release capsules (CD)
Blood and the lymphatic system disorders: thrombocytopenia
Cardiac disorders: cardiac arrest, sudden death
Immune system disorders: angioedema
Musculoskeletal and connective tissue disorders: rhabdomyolysis
Psychiatric disorders: abnormal behavior, aggression, anxiety, irritability, obsessive-compulsive disorder, suicidal behavior (including completed suicide), libido changes, serotonin syndrome in combination with serotonergic drugs
Nervous System Disorder: migraine, reversible ischemic neurological deficit, bruxism
Skin and subcutaneous tissue disorders: fixed drug eruption
Vascular disorders: peripheral coldness, Raynaud’s phenomenon
Adverse Reactions with Other Methylphenidate Hydrochloride Products
Blood and the lymphatic system disorders: leukopenia, anemia, pancytopenia
Cardiac disorders: palpitations; increased blood pressure, tachycardia, angina pectoris, cardiac arrhythmia, myocardial infarction, bradycardia, extrasystole
Eye disorders: blurred vision, difficulties in visual accommodation, diplopia, mydriasis
Gastrointestinal disorders: nausea, abdominal pain, dry mouth, vomiting, dyspepsia, diarrhea, constipation
General Disorders: fatigue, hyperpyrexia
Hepatobiliary disorders: abnormal liver function, ranging from transaminase elevation to severe hepatic injury
Immune system disorders: hypersensitivity, including anaphylaxis, auricular swelling, bullous conditions, eruptions, exanthemas
Infections and infestations: nasopharyngitis
Metabolism and nutrition disorders: decreased appetite, reduced weight gain and suppression of growth during prolonged use in pediatric patients
Musculoskeletal and connective tissue disorders: arthralgia, muscle cramps, myalgia, muscle twitching
Nervous System Disorder: nervousness, dizziness, headache, dyskinesia, including choreoatheetoid movements, drowsiness, tremor, convulsions, cerebrovascular disorders (including vasculitis, cerebral hemorrhages and cerebrovascular accidents), serotonin syndrome in combination with serotonergic drugs
Psychiatric disorders: depressed mood, restlessness, agitation, psychosis (sometimes with visual and tactile hallucinations), affect liability, mania, disorientation
Renal and urinary disorders: hematuria
Reproductive system and breast disorders: gynecomastia
Respiratory, thoracic and mediastinal disorders: pharyngolaryngeal pain, dyspnea, cough
Skin and subcutaneous tissue disorders: scalp hair loss, hyperhidrosis, angioneurotic edema, erythema, exfoliative dermatitis, thrombocytopenic purpura, urticaria, erythema multiforme rash
Urogenital disorders: priapism
Vascular disorders: isolated cases of cerebral arteritis and/or occlusion
Table 3 presents clinically important drug interactions with methylphenidate hydrochloride extended-release capsules (CD).
Monoamine Oxidase Inhibitors (MAOI) |
|
Clinical Impact: |
Concomitant use of MAOIs and CNS stimulants, including, methylphenidate hydrochloride extended-release capsules (CD) can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure [see Contraindications (4)]. |
Intervention: |
Concomitant use of methylphenidate hydrochloride extended-release capsules (CD) with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOI treatment is contraindicated. |
Antihypertensive Drugs |
|
Clinical Impact: |
Methylphenidate hydrochloride extended-release capsules (CD) may decrease the effectiveness of drugs used to treat hypertension [see Warnings and Precautions (5.3)]. |
Intervention: |
Adjust the dosage of the antihypertensive drug as needed. |
Risperidone |
|
Clinical Impact: |
Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS). |
Intervention: |
Monitor for signs of EPS. |
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including methylphenidate hydrochloride extended-release capsules (CD), during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388.
Risk Summary
Published studies and postmarketing reports on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There may be risks to the fetus associated with the use of CNS stimulants use during pregnancy (see Clinical Considerations).
No effects on morphological development were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 10 and 15 times, respectively, the maximum recommended human dose (MRHD) of 60 mg/day given to adolescents on a mg/m2 basis. However, spina bifida was observed in rabbits at a dose 53 times the MRHD given to adolescents. A decrease in pup body weight was observed in a pre-and post-natal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 6 times the MRHD given to adolescents (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations
Fetal/Neonatal Adverse Reactions
CNS stimulants, such as methylphenidate hydrochloride extended-release capsules (CD), can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers.
Animal Data
In embryo-fetal development studies conducted in rats and rabbits, methylphenidate was administered orally at doses of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Malformations (increased incidence of fetal spina bifida) were observed in rabbits at the highest dose, which is approximately 52 times the MRHD of 60 mg/day given to adolescents on a mg/m2 basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (15 times the MRHD given to adolescents on a mg/m2 basis). There was no evidence of morphological development effects in rats, although increased incidences of fetal skeletal variations were seen at the highest dose level (10 times the MRHD of 60 mg/day given to adults on a mg/m2 basis), which was also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (3 times the MRHD on a mg/m2 basis). When methylphenidate was administered to rats throughout pregnancy and lactation at doses of up to 45 mg/kg/day, offspring body weight gain was decreased at the highest dose (6 times the MRHD of 60 mg/day given to adults on a mg/m2 basis), but no other effects on postnatal development were observed. The no effect level for pre-and postnatal development in rats was 15 mg/kg/day (~2 times the MRHD given to adolescents on a mg/m2 basis).
Risk Summary
Limited published literature, based on milk sampling from seven mothers reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for methylphenidate hydrochloride extended-release capsules (CD) and any potential adverse effects on the breastfed infant from methylphenidate hydrochloride extended-release capsules (CD) or from the underlying maternal condition.
Clinical Considerations
Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain.
The safety and effectiveness of methylphenidate hydrochloride extended-release capsules (CD) for the treatment of ADHD have been established in pediatric patients 6 to 15 years of age. The safety and effectiveness of methylphenidate hydrochloride extended-release capsules (CD) in pediatric patients younger than 6 years of age have not been established. Long-term efficacy of methylphenidate hydrochloride extended-release capsules (CD) in pediatric patients have not been established.
Long-Term Suppression of Growth
Growth should be monitored during treatment with stimulants, including methylphenidate hydrochloride extended-release capsules (CD). Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted [see Warnings and Precautions (5.6)].
Juvenile Animal Toxicity Data.
In a study conducted in young rats, methylphenidate was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal Day 7) and continuing through sexual maturity (postnatal Week 10). When these animals were tested as adults (postnatal Weeks 13 to 14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day (approximately 6 times the MRHD on a mg/m2 basis) or greater, and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dose (12 times the MRHD on a mg/m2 basis). The no effect level for juvenile neurobehavioral development in rats was 5 mg/kg/day (half the MRHD on a mg/m2 basis). The clinical significance of the long-term behavioral effects observed in rats is unknown.
Methylphenidate hydrochloride extended-release capsules (CD) contain methylphenidate hydrochloride, a Schedule II controlled substance.
CNS stimulants, including methylphenidate hydrochloride extended-release capsules (CD), other methylphenidate-containing products, and amphetamines have a high potential for abuse. Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physicological effect. Drug addiction is a cluster of behavioral, cognitive, and psychological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Both abuse and misuse may lead to addiction, and some individuals may develop addiction even when taking methylphenidate hydrochloride extended-release capsules (CD) as prescribed.
Signs and symptoms of CNS stimulant abuse include increased heart rate, respiratory rate, blood pressure, and/or sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss of coordination, tremors, flushed skin, vomiting, and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed. Individual who abuser CNS stimulants may chew, snort, inject, or use other unapproved routes of administration which can result in overdose and death [see Overdosage (10)].
To reduce the abuse of methylphenidate hydrochloride extended-release capsules (CD), assess the risk of abuse prior to prescribing. After prescribing, keep careful prescription records, educate patients and their families about abuse and on proper storage and disposal of CNS stimulants [see How Supplied/Storage and Handling (16)], monitor for signs of abuse while on therapy, and re-evaluate the need for methylphenidate hydrochloride extended-release capsule (CD) use.
Physical Dependence
Methylphenidate hydrochloride extended-release capsules (CD) may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by a withdrawal signs and symptoms after abrupt discontinuation or significant dose reduction of a drug. Withdrawal symptoms after abrupt cessation following prolonged high-dosage administration of CNS stimulants include dysphoric mood; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.
Tolerance
Methylphenidate hydrochloride extended-release capsules (CD) may produce tolerance from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).
Human Experience
Signs and symptoms of acute methylphenidate overdosage, resulting principally from overstimulation of the CNS and from excessive sympathomimetic effects, may include the following: nausea, vomiting, diarrhea, restlessness, anxiety, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, hypotension, tachypnea, mydriasis, dryness of mucous membranes, and rhabdomyolysis.
Overdose Management
Consult with a Certified Poison Control Center (1-800-222-1222) for guidance and advice on the management of overdosage with methylphenidate. Provide supportive care, including close medication supervision and monitoring. Treatment should consist of those general measures employed in the management of overdosage with any drug. Consider the possibility of multiple drug overdosage.
Methylphenidate hydrochloride extended-release capsules (CD) contains methylphenidate hydrochloride, a CNS stimulant. The extended-release capsules provide 30% of the dose by the immediate release (IR) component and 70% of the dose by an extended release (ER) component in a single bead type. Methylphenidate hydrochloride extended-release capsules (CD) is available in six capsule strengths containing 10 mg (3 mg IR; 7 mg ER), 20 mg (6 mg IR; 14 mg ER), 30 mg (9 mg IR; 21 mg ER), 40 mg (12 mg IR; 28 mg ER), 50 mg (15 mg IR; 35 mg ER), or 60 mg (18 mg IR; 42 mg ER) of methylphenidate hydrochloride, USP for oral administration.
Chemically, methylphenidate hydrochloride, USP is d,l (racemic)-threo-methyl α-phenyl-2-piperidineacetate hydrochloride. Its molecular formula is C14H19NO2•HCl. Its structural formula is:
Methylphenidate hydrochloride, USP is a white to off-white powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77.
Methylphenidate hydrochloride extended-release capsules (CD) also contain the following inactive ingredients: cetyl alcohol, corn starch, D&C Yellow #10 aluminum lake, dibutyl sebacate, ethylcellulose, FD&C Blue #1 aluminum lake, FD&C Blue #2 aluminum lake, FD&C Red #40 aluminum lake, gelatin, hypromellose, iron oxide black, propylene glycol, shellac glaze, sodium lauryl sulfate, sucrose, and titanium dioxide. Additionally, the 10 mg capsules contain D&C Yellow #10 and FD&C Green #3; the 20 mg capsules contain FD&C Blue #1; the 30 mg capsules contain iron oxide red and iron oxide yellow; the 40 mg capsules contain iron oxide red, and iron oxide yellow; the 50 mg capsules contain FD&C Blue #1.
Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. The mode of therapeutic action in ADHD is not known.
Methylphenidate is a racemic mixture comprised of the d- and l-threo enantiomers. The d-threo enantiomer is more pharmacologically active than the l-threo enantiomer. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space.
Following one week of once-daily doses of 20 mg or 40 mg methylphenidate hydrochloride extended-release capsules (CD) to children aged 7 to12 years old with ADHD, Cmax and AUC of methylphenidate were approximately proportional to the administered doses.
Absorption
Following administration of methylphenidate hydrochloride extended-release capsules (CD) in children aged 7 to 12 years old with ADHD, the plasma concentration time profile of methylphenidate showed two phases of drug release with a sharp, initial slope similar to a methylphenidate immediate-release tablet (median Tmax1 about 1.5 hours post dose), and a second rising portion approximately three hours later (median Tmax2 about 4.5 hours post dose)*, followed by a gradual decline (Figure 1). The means for Cmax and area under the curve (AUC) following a dose of 20 mg were slightly lower than those seen with 10 mg of the immediate-release formulation, dosed at 0 and 4 hours.
*25% to 30% of the subjects had only one observed peak (Cmax) concentration of methylphenidate.
Figure 1: Comparison of Immediate Release (IR) and Methylphenidate Hydrochloride Extended-Release Capsule (CD) Formulations After Repeated Doses of
Methylphenidate Hydrochloride in Pediatric Patients 7 to 12 Years of Age with ADHD
Effect of Food
Ingestion of a high-fat meal with methylphenidate hydrochloride extended-release capsules (CD) increased the mean Cmax and AUC of methylphenidate by about 30% and 17%, respectively. The presence of food delayed the early peak by approximately 1 hour (range -2 to 5 hours delay) [see Dosage and Administration (2.1)].
The bioavailability (Cmax and AUC) of methylphenidate was unaffected by sprinkling the methylphenidate hydrochloride extended-release capsule (CD) contents on applesauce as compared to the intact capsule.
Effect of Alcohol
At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first hour, resulting in 84% of the methylphenidate being released. The results with the 60 mg capsule are considered to be representative of the other available capsule strengths [see Drug Interactions (7)].
Distribution
Plasma protein binding is 10% to 33%. The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.
Elimination
The mean terminal half-life (t½) of methylphenidate following administration of methylphenidate hydrochloride extended-release capsules (CD) (t½=6.8 hours) is longer than the mean terminal t½ following administration of methylphenidate hydrochloride immediate-release tablets (t½=2.9 hours) and methylphenidate hydrochloride extended-release tablets (t½=3.4 hours) in healthy adult volunteers.
Metabolism
In vitro studies showed that methylphenidate was not metabolized by cytochrome P450 isoenzymes. Methylphenidate is metabolized primarily by deesterification to alpha-phenyl-piperidine acetic acid (ritalinic acid), which has little or no pharmacologic activity.
Excretion
After oral administration of radiolabeled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was ritalinic acid, accounting for approximately 80% of the dose.
Specific Populations
Male and Female Patients
The pharmacokinetics of methylphenidate after a single dose of methylphenidate hydrochloride extended-release capsules (CD) were similar between adult men and women.
Racial or Ethnic Groups
The influence of race on the pharmacokinetics of methylphenidate after methylphenidate hydrochloride extended-release capsule (CD) administration has not been studied.
Pediatric Patients
The pharmacokinetics of methylphenidate after methylphenidate hydrochloride extended-release capsule (CD) administration has not been studied in children less than 6 years of age.
Patients with Renal Impairment
Methylphenidate hydrochloride extended-release capsules (CD) have not been studied in patients with renal insufficiency. Since renal clearance is not an important route of methylphenidate clearance, and the major metabolite (ritalinic acid), has little or no pharmacologic activity, renal insufficiency is expected to have minimal effect on the pharmacokinetics of methylphenidate hydrochloride extended-release capsules (CD).
Patients with Hepatic Impairment
Methylphenidate hydrochloride extended-release capsules (CD) have not been studied in patients with hepatic insufficiency. Hepatic impairment is expected to have minimal effect on the pharmacokinetics of methylphenidate since it is metabolized primarily to ritalinic acid by nonmicrosomal hydrolytic esterases that are widely distributed throughout the body
Drug Interaction Studies
In vitro studies showed that methylphenidate did not inhibit cytochrome P450 isoenzymes at clinically observed plasma drug concentrations.
Carcinogenesis
In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas, at a daily dose of approximately 60 mg/kg per day. This dose is approximately 2 times the maximum recommended human dose (MRHD) of 60 mg/day given to children on a mg/m2 basis.
Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors, and the significance of these results to humans is unknown.
Methylphenidate did not cause any increases in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dose used was approximately 45 mg/kg/day, which is approximately 4 times the MRHD (children) on a mg/m2 basis.
In a 24-week carcinogenicity study in the transgenic mouse strain p53+/-, which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. Male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dose groups were exposed to 60 to 74 mg/kg per day of methylphenidate.
Mutagenesis
Methylphenidate was not mutagenic in the in vitro Ames reverse mutation assay, in the in vitro mouse lymphoma cell forward mutation assay, or in the in vitro chromosomal aberration assay using human lymphocytes. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an in vitro assay in cultured Chinese Hamster Ovary cells. Methylphenidate was negative in vivo in males and females in the mouse bone marrow micronucleus assay.
Impairment of Fertility
Methylphenidate did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week continuous breeding study. The study was conducted at doses up to 160 mg/kg per day, approximately 10 times the maximum recommended human dose of 60 mg/day given to adolescents on a mg/m2 basis.
Methylphenidate hydrochloride extended-release capsules (CD) were evaluated in a double-blind, parallel-group, placebo-controlled trial in which 321 untreated or previously treated pediatric patients with a DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), 6 to 15 years of age, received a single morning dose for up to 3 weeks. Patients were required to have the combined or predominantly hyperactive-impulsive subtype of ADHD; patients with the predominantly inattentive subtype were excluded. Patients randomized to the methylphenidate hydrochloride extended-release capsules (CD) group received 20 mg daily for the first week. Their dosage could be increased weekly to a maximum of 60 mg by the third week, depending on individual response to treatment.
The patient’s regular school teacher completed the teachers’ version of the Conners’ Global Index Scale (TCGIS), a scale for assessing ADHD symptoms, in the morning and again in the afternoon on three alternate days of each treatment week. The primary efficacy endpoint was determined by the average of the total scores for the 10-item TCGIS completed by the classroom teacher in the morning and again in the afternoon on the three observation days during the last week of double-blind therapy.
Patients treated with methylphenidate hydrochloride extended-release capsules (CD) showed a statistically significant improvement in symptom scores from baseline over patients who received placebo (See Figure 2). Separate analyses of TCGIS scores in the morning and afternoon revealed superiority in improvement with methylphenidate hydrochloride extended-release capsules (CD) over placebo during both time periods (See Figure 3).
Figure 2: Least Squares Mean Change from Baseline in TCGIS Total Score in Pediatric Patients 6 to 15 years of Age with ADHD
Figure 3: Least Squares Mean Change from Baseline in TCGIS Total Score in Pediatric Patients 6 to 15 years of Age with ADHD: Morning (AM) and Afternoon (PM)
* FIGURES 2 & 3: Last observation carried forward analysis at week 3.
Error bars represent the standard error of the mean.
How Supplied
Methylphenidate hydrochloride extended-release capsules (CD) are available in six strengths (see Table 4):
Strength |
Capsule Color |
Imprinting on Capsule Cap and Body |
Capsules per Bottle |
NDC Number |
10 mg |
light green opaque cap /white opaque body |
“93” over “5295” |
100 |
NDC 0093-5295-01 |
20 mg |
light turquoise blue opaque cap/white opaque body |
“93” over “5296” |
100 |
NDC 0093-5296-01 |
30 mg |
light brown opaque cap /white opaque body |
“93” over “5297” |
100 |
NDC 0093-5297-01 |
40 mg |
light brown opaque cap/white opaque body |
“93” over “5298” |
100 |
NDC 0093-5298-01 |
50 mg |
light blue opaque cap/white opaque body |
“93” over “5292” |
100 |
NDC 0093-5292-01 |
60 mg |
white opaque cap/white opaque body |
“93” over “5293” |
100 |
NDC 0093-5293-01 |
Storage and Handling
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).
Keep this and all medications out of the reach of children.
Disposal
Comply with local laws and regulations on drug disposal of CNS stimulants. Dispose of remaining, unused, or expired methylphenidate hydrochloride extended-release capsules (CD) by a medicine take-back program or by an authorized collector registered with the Drug Enforcement Administration. If no take-back program or authorized collector is available, mix methylphenidate hydrochloride extended-release capsules (CD) with an undesirable, nontoxic substance to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and discard methylphenidate hydrochloride extended-release capsules (CD) in the household trash.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Controlled Substance Status/Potential for Abuse and Dependence
Advise patients and their caregivers that methylphenidate hydrochloride extended-release capsules (CD) are a federally controlled substance, and it can be abused and lead to dependence [see Drug Abuse and Dependence (9.1, 9.2, and 9.3)]. Instruct patients that they should not give methylphenidate hydrochloride extended-release capsules (CD) to anyone else. Advise patients to store methylphenidate hydrochloride extended-release capsules (CD) in a safe place, preferably locked, to prevent abuse. Advise patients to comply with laws and regulations on drug disposal. Advise patients to dispose of remaining, unused, or expired methylphenidate hydrochloride extended-release capsules (CD) by a medicine take-back program if available [see Warnings and Precautions (5.1), Drug Abuse and Dependence (9), How Supplied/Storage and Handling (16)].
Administration Instructions
Instruct patients and their caregivers that the methylphenidate hydrochloride extended-release capsules (CD) and the capsule contents must not be crushed or chewed. Instruct patients that the capsule may be swallowed whole, or alternatively, the capsule may be opened and the capsule contents sprinkled onto a small amount (tablespoon) of applesauce and given immediately, and not stored for future use [see Dosage and Administration (2.3)].
Serious Cardiovascular Risks
Advise patients and their caregivers that there is a potential for serious cardiovascular risks including sudden death, myocardial infarction, stroke, and hypertension with methylphenidate hydrochloride extended-release capsule (CD) use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease [see Warnings and Precautions (5.2)].
Blood Pressure and Heart Rate Increases
Instruct patients and their caregivers that methylphenidate hydrochloride extended-release capsules (CD) can cause elevations of their blood pressure and pulse rate [see Warnings and Precautions (5.3)].
Psychiatric Risks
Advise patients and their caregivers that methylphenidate hydrochloride extended-release capsules (CD), at recommended doses, can cause psychotic or manic symptoms, even in patients without a prior history of psychotic symptoms or mania [see Warnings and Precautions (5.4)].
Priapism
Advise patients and their caregivers of the possibility of painful or prolonged penile erections (priapism). Instruct the patient to seek immediate medical attention in the event of priapism [see Warnings and Precautions (5.5)].
Circulation Problems in Fingers and Toes (peripheral vasculopathy, including Raynaud’s phenomenon)
Suppression of Growth
Advise patients and their caregivers that methylphenidate hydrochloride extended-release capsules (CD) can cause slowing of growth and weight loss [see Warnings and Precautions (5.7)].
Pregnancy Registry
Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to methylphenidate hydrochloride extended-release capsules (CD) during pregnancy [see Use in Specific Populations (8.1)].
Alcohol Use
Advise patients to avoid alcohol while taking methylphenidate hydrochloride extended-release capsules (CD). Consumption of alcohol while taking methylphenidate hydrochloride extended-release capsules (CD) may result in a more rapid release of the dose of methylphenidate [see Drug Interactions (7)].
Brands listed are the trademarks of their respective owners.
Dispense with Medication Guide available at: www.tevausa.com/medguides
Manufactured For:
Teva Pharmaceuticals
Parsippany, NJ 07054
Rev. S 11/2022
Dispense with Medication Guide available at: www.tevausa.com/medguides
MEDICATION GUIDE |
What is the most important information I should know about methylphenidate hydrochloride extended-release capsules (CD)? Methylphenidate hydrochloride extended-release capsules (CD) can cause serious side effects, including:
Tell your healthcare provider about any mental problems your child has, or about a family history of, suicide, bipolar illness, or depression. Call your healthcare provider right away if your child has any new or worsening mental symptoms or problems during treatment with methylphenidate hydrochloride extended-release capsules (CD), especially hearing voices, seeing or believing things that are not real, or new manic symptoms. |
What are methylphenidate hydrochloride extended-release capsules (CD)? Methylphenidate hydrochloride extended-release capsules (CD) are a prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 to 15 years of age. Methylphenidate hydrochloride extended-release capsules (CD) may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD. It is not known if methylphenidate hydrochloride extended-release capsules (CD) are safe and effective for use in children younger than 6 years of age or older than 15 years of age. Methylphenidate hydrochloride extended-release capsules (CD) are a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs. Keep methylphenidate hydrochloride extended-release capsules (CD) in a safe place to protect it from theft. Never give your methylphenidate hydrochloride extended-release capsules (CD) to anyone else, because it may cause death or harm them. Selling or giving away methylphenidate hydrochloride extended-release capsules (CD) may harm others and is against the law. |
Who should not take Methylphenidate hydrochloride extended-release capsules (CD)? Your child should not take methylphenidate hydrochloride extended-release capsules (CD) if your child:
|
Before starting methylphenidate hydrochloride extended-release capsules (CD) tell your healthcare provider about all your child’s medical conditions, including: if your child:
Tell your healthcare provider about all the medicines that your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Methylphenidate hydrochloride extended-release capsules (CD) and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with methylphenidate hydrochloride extended-release capsules (CD). Your healthcare provider will decide whether methylphenidate hydrochloride extended-release capsules (CD) can be taken with other medicines. Especially tell your healthcare provider if your child takes a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI). Know the medicines that your child takes. Keep a list of the medicines with you to show your healthcare provider and pharmacist. Your child should not start taking any new medicines during treatment with methylphenidate hydrochloride extended-release capsules (CD) without talking to your healthcare provider first. |
How should methylphenidate hydrochloride extended-release capsules (CD) be taken?
|
What should be avoided during treatment with methylphenidate hydrochloride extended-release capsules (CD)? |
What are the possible side effects of methylphenidate hydrochloride extended-release capsules (CD)?
Tell your healthcare provider if your child has numbness, pain, skin color change, or sensitivity to temperature in the fingers or toes. Call your healthcare provider right away if your child has any signs of unexplained wounds appearing on the fingers or toes during treatment with methylphenidate hydrochloride extended-release capsules (CD).
The most common side effects of methylphenidate hydrochloride extended-release capsules (CD) include anorexia and trouble sleeping. These are not all the possible side effects of methylphenidate hydrochloride extended-release capsules (CD). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store methylphenidate hydrochloride extended-release capsules (CD)?
Keep methylphenidate hydrochloride extended-release capsules (CD) and all medicines out of the reach of children |
General information about the safe and effective use of methylphenidate hydrochloride extended-release capsules (CD). Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use methylphenidate hydrochloride extended-release capsules (CD) for a condition for which it was not prescribed. Do not give methylphenidate hydrochloride extended-release capsules (CD) to other people, even if they have the same symptoms. It may harm them and it is against the law. You can ask your healthcare provider or pharmacist for information about methylphenidate hydrochloride extended-release capsules (CD) that was written for healthcare professionals. |
What are the ingredients in methylphenidate hydrochloride extended-release capsules (CD)? Active Ingredient: methylphenidate hydrochloride Inactive Ingredients: cetyl alcohol, corn starch, D&C Yellow #10 aluminum lake, dibutyl sebacate, ethylcellulose, FD&C Blue #1 aluminum lake, FD&C Blue #2 aluminum lake, FD&C Red #40 aluminum lake, gelatin, hypromellose, iron oxide black, propylene glycol, shellac glaze, sodium lauryl sulfate, sucrose, and titanium dioxide. Additionally, the 10 mg capsules contain D&C Yellow #10 and FD&C Green #3; the 20 mg capsules contain FD&C Blue #1; the 30 mg capsules contain iron oxide red and iron oxide yellow; the 40 mg capsules contain iron oxide red, and iron oxide yellow; the 50 mg capsules contain FD&C Blue #1. Brands listed are the trademarks of their respective owners. Manufactured For: Teva Pharmaceuticals, Parsippany, NJ 07054 For more information call Teva at 1-888-838-2872. |
This Medication Guide has been approved by the U.S. Food and Drug Administration. Rev. L 11/2022
NDC 0093-5295-01
Once Daily
Methylphenidate HCl Extended-Release Capsules (CD) CII
10 mg
PHARMACIST: Dispense the accompanying Medication Guide to each patient.
Rx only
100 Capsules
NDC 0093-5296-01
Once Daily
Methylphenidate HCl Extended-Release Capsules (CD) CII
20 mg
PHARMACIST: Dispense the accompanying Medication Guide to each patient.
Rx only
100 Capsules
NDC 0093-5297-01
Once Daily
Methylphenidate HCl Extended-Release Capsules (CD) CII
30 mg
PHARMACIST: Dispense the accompanying Medication Guide to each patient.
Rx only
100 Capsules
NDC 0093-5298-01
Once Daily
Methylphenidate HCl Extended-Release Capsules (CD) CII
40 mg
PHARMACIST: Dispense the accompanying Medication Guide to each patient.
Rx only
100 Capsules
METHYLPHENIDATE HYDROCHLORIDE
(CD)
methylphenidate hydrochloride capsule, extended release |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
METHYLPHENIDATE HYDROCHLORIDE
(CD)
methylphenidate hydrochloride capsule, extended release |
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
METHYLPHENIDATE HYDROCHLORIDE
(CD)
methylphenidate hydrochloride capsule, extended release |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
METHYLPHENIDATE HYDROCHLORIDE
(CD)
methylphenidate hydrochloride capsule, extended release |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
METHYLPHENIDATE HYDROCHLORIDE
(CD)
methylphenidate hydrochloride capsule, extended release |
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
METHYLPHENIDATE HYDROCHLORIDE
(CD)
methylphenidate hydrochloride capsule, extended release |
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
|
Labeler - Teva Pharmaceuticals USA, Inc. (001627975) |